PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INSULET CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$141.96+0.86 (+0.61%)
Close on Oct 19, 2026
- Market cap
- $9.85B
- P/E (TTM)
- 26.5
- Dividend yield
- –
INSULET CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Omnipod products | $795.90M | $758.40M | $781.80M | $699.20M | $639.00M | $554.00M | $585.70M | $533.50M | $480.40M | $433.00M | $501.00M | $422.00M | 99.3% | +24.6% |
| U.S. | $544.10M | $515.60M | $567.80M | $497.10M | $453.20M | $401.70M | $443.70M | $395.60M | $352.30M | $317.70M | $394.60M | $320.60M | 67.9% | +20.1% |
| International | $251.80M | $242.90M | $214.10M | $202.10M | $185.80M | $152.30M | $142.00M | $137.90M | $128.20M | $115.30M | $106.40M | $101.40M | 31.4% | +35.5% |
| Drug Delivery | $5.80M | $3.30M | $1.90M | $7.10M | $10.20M | $14.90M | $11.80M | $10.30M | $8.10M | $8.70M | $8.80M | $10.70M | 0.7% | -43.1% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $549.90M | $518.80M | $569.80M | $504.20M | $463.30M | $416.60M | $455.40M | $406.00M | $360.30M | $326.40M | – | – | 68.6% | +18.7% |
| International | $251.80M | $242.90M | $214.10M | $202.10M | $185.80M | $152.30M | $142.00M | $137.90M | $128.20M | $115.30M | – | – | 31.4% | +35.5% |
From the segment and revenue-disaggregation notes of Insulet's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.